Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $19.50

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.50.

Several equities research analysts have weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th.

Enanta Pharmaceuticals Stock Up 2.2 %

NASDAQ:ENTA opened at $8.76 on Friday. The company’s 50 day moving average is $10.72 and its 200-day moving average is $12.18. Enanta Pharmaceuticals has a 12 month low of $8.00 and a 12 month high of $17.80. The firm has a market cap of $185.62 million, a price-to-earnings ratio of -1.60 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The company’s quarterly revenue was down 22.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) EPS. Research analysts predict that Enanta Pharmaceuticals will post -5.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ENTA. Allspring Global Investments Holdings LLC bought a new stake in Enanta Pharmaceuticals in the second quarter valued at $35,000. US Bancorp DE increased its stake in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $122,000. Quest Partners LLC boosted its stake in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock worth $150,000 after buying an additional 9,692 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Enanta Pharmaceuticals in the first quarter valued at approximately $191,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.